ProMIS Neurosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

NET LOSS PER SHARE

NET LOSS PER SHARE

12 Months Ended

Dec. 31, 2022

NET LOSS PER SHARE

NET LOSS PER SHARE

17.

NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders:


	Years Ended December 31,
	2022		2021
Numerator:
Net loss attributable to common shareholders	$	18,062,263	$	9,790,106
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders, basic and diluted		7,502,609		5,785,617
Net loss per share attributable to common shareholders, basic and diluted	$	(2.41)	$	(1.69)

The following outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:


	December 31,
	2022	2021
Options issued and outstanding under stock option plan	1,043,025	738,037
Warrants	1,873,622	1,560,688
Convertible debt	—	1,166,667
Series 1 Convertible Preferred Shares	1,166,667	—
Deferred Share Units	1,061	1,061
Total	4,084,375	3,466,453